BP
MRVI icon

Ballentine Partners’s Maravai LifeSciences MRVI Stock Holding History

Ballentine Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,253
Closed -$29K – 1116
2026
Q1 		$29K Sell
10,253
-2,648
-21% -$8.98K ﹤0.01% 1007
2025
Q4 		$41.9K Buy
12,901
+75
+0.6% +$252 ﹤0.01% 996
2025
Q3 		$36.8K Buy
+12,826
New +$32.8K ﹤0.01% 1009

Other funds holding MRVI

DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Ballentine Partners's MRVI Position: Q2 2026 in Review

Ballentine Partners sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 10,253 shares — an estimated $29K sold.

Ballentine Partners first reported a position in MRVI in Q3 2025 and held it in 3 quarters. The position peaked at $41.9K in Q4 2025. 4 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Ballentine Partners reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
  • Ballentine Partners sold 10,253 Maravai LifeSciences shares in Q2 2026, an estimated $29K.
  • Ballentine Partners first reported a position in Maravai LifeSciences in Q3 2025 and held it in 3 quarters.
  • Ballentine Partners's Maravai LifeSciences position peaked at $41.9K in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.